Dermira Inc (NASDAQ:DERM)’s share price traded up 15.4% on Monday . The company traded as high as $9.26 and last traded at $9.09, 1,664,550 shares changed hands during mid-day trading. An increase of 38% from the average session volume of 1,209,927 shares. The stock had previously closed at $7.88.
Several analysts have issued reports on DERM shares. Leerink Swann decreased their price objective on shares of Dermira from $23.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Zacks Investment Research upgraded Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 target price for the company in a research report on Wednesday, October 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Dermira in a research note on Friday, October 18th. Finally, BidaskClub upgraded Dermira from a “strong sell” rating to a “sell” rating in a report on Saturday, October 19th. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $16.80.
The stock has a market capitalization of $429.63 million, a PE ratio of -1.73 and a beta of 1.37. The company has a quick ratio of 6.63, a current ratio of 7.03 and a debt-to-equity ratio of 25.08. The stock’s 50 day moving average price is $7.69 and its 200-day moving average price is $8.21.
In other Dermira news, Director Matthew K. Fust sold 6,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $8.77, for a total value of $52,620.00. Following the completion of the sale, the director now directly owns 11,051 shares of the company’s stock, valued at approximately $96,917.27. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 12.40% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co NY increased its holdings in Dermira by 57.4% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 16,847 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 6,141 shares during the period. Millennium Management LLC increased its stake in shares of Dermira by 747.5% during the third quarter. Millennium Management LLC now owns 409,129 shares of the biopharmaceutical company’s stock valued at $2,614,000 after buying an additional 360,852 shares during the period. Squarepoint Ops LLC increased its stake in shares of Dermira by 12.2% during the third quarter. Squarepoint Ops LLC now owns 178,732 shares of the biopharmaceutical company’s stock valued at $1,142,000 after buying an additional 19,480 shares during the period. Great Point Partners LLC increased its stake in shares of Dermira by 68.8% during the third quarter. Great Point Partners LLC now owns 2,621,333 shares of the biopharmaceutical company’s stock valued at $16,750,000 after buying an additional 1,068,433 shares during the period. Finally, California State Teachers Retirement System raised its holdings in shares of Dermira by 2.6% in the third quarter. California State Teachers Retirement System now owns 73,649 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 1,857 shares in the last quarter. Institutional investors own 94.75% of the company’s stock.
About Dermira (NASDAQ:DERM)
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Story: Why is the Consumer Price Index (CPI) important?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.